|Bid||57.61 x 2900|
|Ask||57.65 x 1200|
|Day's Range||57.44 - 58.09|
|52 Week Range||56.66 - 69.75|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 03, 2021 - Nov. 08, 2021|
|Forward Dividend & Yield||1.96 (3.20%)|
|Ex-Dividend Date||Sep. 30, 2021|
|1y Target Est||80.24|
In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss two upcoming U.S. Food and Drug Administration (FDA) approval decisions that investors should keep an eye on. Keith Speights: Brian, on another note, the FDA is set to make several important approval decisions in the fourth quarter. Brian Orelli: Biomarin (NASDAQ: BMRN) has one coming up on Nov. 20.
NEW ORLEANS, Oct. 22, 2021 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: The Boston Beer Company, Inc. (SAM)Class Period: 4/22/2021 - 9/8/2021 Lead Plaintiff Motion Deadline: November 15, 2021SECURITIES FRAUD To learn more, visit https://claimsfiler.com/cases/nyse-sam/ The Honest Company, Inc. (HNST)Class Period: purchase of shares issued either in or after the May 2021 Initial Pu
Aurinia's shares closed up nearly 27% on the news, giving it a market capitalization of $3.59 billion, according to Refinitiv data. The report said no final decision has been made and that Bristol Myers could opt out of a potential deal. Both Bristol Myers and Aurinia declined to comment on the matter.